Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023)
Palvella Therapeutics (PVLA) reported Preferred Stock Liabilities of $70.6 million for Q4 2023, little changed year-over-year from $70.6 million in Q4 2022, and little changed quarter-over-quarter from $70.6 million in Q4 2022.
Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Preferred Stock Liabilities data on file, last reported at $70.6 million in Q4 2023.
- Preferred Stock Liabilities for Q4 2023 came in at $70.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2023 was $70.6 million (changed 0.0% YoY), and the FY2023 annual result was $70.6 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities held at $70.6 million in Q4 2023 per PVLA's latest filing, from $70.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $70.6 million in Q4 2022 and troughed at $70.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 70.60 Mn |
| Dec 31, 2022 | 70.60 Mn |